ASN is a not-for-profit organization of 11

ASN is a not-for-profit organization of 11,000 physicians and scientists dedicated to the study of nephrology and are committed to providing a forum for the dissemination of information about the latest research and clinical findings on kidney diseases. ASN publishes JASN, the Clinical Journal of the American Society of Nephrology , and the Nephrology Self – Assessment Program . In January 2009, the company will launch ASN Kidney News, a newsmagazine for nephrologists, scientists, allied health professionals and staff.

Numerous studies have shown that persistent disparities exist in end-stage renal disease and kidney transplantation. Black patients with ESRD comprise more than a third of the kidney transplant waiting list but are 2.7 times less likely to. Kidney transplantation than their white counterparts In addition, patients with black skin are often compared kidney failure kidney failure after transplantation with whites.

read more

Forward-Looking Statementsinclude the statements in this press release which are not severely historical are forward-looking statements such statements but not limited but are not restricted at, evidence of metabase ‘ product pipeline, capacities and long-term goals limited Such forwardlooking statements. Certain known and unknown risk, uncertainties and other factors, proprietary technology differ materially from materially from Metabasis historic findings or from any results expressed or implied of those forward-looking statements. Such factors include, but are is not limited to, risks and limit uncertainty about the progress made and time of clinical trials for Metabasis ‘ drug candidates, by the fact that positive results from preclinical studies and early clinical studies does not necessarily later clinical trials to be successful will, difficult and delay in the development, testing, obtaining regulatory approval, production and marketing metabase ‘ product candidates; serious side effects and insufficient efficacy to and serious adverse events were related, Metabasis ‘ product candidates or proprietary technologies, is the risk that Metabasis is not of the the, forward-looking statements view more value or retain rights reserved of selling directly its product candidates; Metabasis ‘ depending on on its licensees and an employee for clinical development and registration , as well as information about specific of its product candidates, any conflicts with employees who are slow down or hinder development or marketing metabase ‘drug candidates, that scope and validity of intellectual property the metabase ‘ drug candidates, proprietary technologies and applications, competitive from other pharmaceutical or biotechnological companies; Metabasis ‘ ability to to obtain additional financing their operations its operations, the ability to maintain to be generated by partnerships; maintaining compliance with Nasdaq Global Market further licensing regulations and other factors detailed in Risk Factors of Quarterly Review on Form 10 – Q is Metabasis of the quarter ended 30 September 2008 discusses All the forward-looking statements is qualified in its entirety. Information or future events metabase provide such information as of that date contradicts of this forward looking statements not undertake to update forward-looking statements press release as press release as a result of new information, future events or for other reasons.

buy tadalafil

Other entries from category "plastic surgery":

Random entries